comparison of glp-1 agonists Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults Compare GLP-1 Options | Ozempic

And when side effects persist beyond the typical 4-6 week adjustment period, switching to an alternative with a different receptor binding profile or mechanism of action often resolves the issue entirely

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

Patients with indicators of high-risk or established ASCVD, chronic kidney disease, or heart failure According to the ADA, when considering an agent for add-on to metformin background therapy, the first recommended consideration is whether or not the patient has indicators of high-risk or established ASCVD, chronic kidney disease (CKD), or heart failure ( Figure 2 )

Erlinger S

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes